Transpire Bio

Transpire Bio is a private, clinical-stage biotech company applying its patented inhalation technology to unlock value from established drug molecules. The company operates a three-pronged business model targeting innovative biopharmaceuticals, co-development partnerships, and complex generics, with an initial pipeline focus on idiopathic pulmonary fibrosis (IPF). Backed by significant manufacturing infrastructure investment, Transpire aims to create improved therapies in high-potential markets like lung disease, CNS, oncology, and obesity.

Proprietary, customizable inhalation formulation and delivery platforms for repurposing drugs with known mechanisms of action via pulmonary delivery. Supported by integrated, US-based R&D and manufacturing facilities.

Competes with large pharma and biotechs in IPF (e.g., Boehringer Ingelheim, Roche) and other target diseases. In inhalation technology, competes with specialized CDMOs and platform companies like Vectura Group (now part of Philip Morris). Complex generics face competition from other generic firms with inhalation expertise.